The Chennai-based pharma major Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) said it has been granted the Certificate of Suitability (CoS) by the European Directorate for Quality of Medicines (EDQM) for its sterile API product Cefazolin Sodium. With this, Orchid has now five CoS approvals, including the recent approval for its API Cefixime.
According to a company release, K Raghavendra Rao, managing director, Orchid Chemicals & Pharmaceuticals Ltd., “Cefazolin is a high margin, premium product that has considerable market potential in Europe besides the US and other regulated markets. With both the US FDA and CoS certifications, we are confident of a good market and revenue share in the US and European markets in the coming quarters.”
Orchid has set up a state of the art manufacturing facility at Alathur near Chennai for the production of APIs, and this plant received USFDA approval in December, last year.